$0.258
+0.009 (+3.36%)收盤時
AIM 資訊
AIM 事件
AIM ImmunoTech Granted New Patent for Cancer Treatment
AIM ImmunoTech announced that the United States Patent and Trademark Office has granted a patent covering the use of the company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer. This newly issued U.S. patent expires December 20, 2039. Ampligen is a wide-spectrum Toll-like receptor 3 agonist, among other biological effects, and has been investigated for the treatment of various cancers, among other conditions. The Company has been issued multiple patents, and has filed multiple additional patent applications, directed to the use of Ampligen for cancer treatment.
AIM ImmunoTech Issues 7.52M Shares at $3.25 Each
AIM ImmunoTech announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7.52M shares of common stock at a purchase price of 3.25c per share. The gross proceeds to the company from the offering are expected to be approximately $2.4M, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the company will issue and sell unregistered Series I warrants to purchase up to 15.04M shares of common stock. The offering is expected to close on or about May 21, subject to the satisfaction of customary closing conditions. Ladenburg Thalmann & Co. is acting as the exclusive placement agent for the offering.
AIM ImmunoTech Accelerates Pancreatic Cancer Program Progress
AIM ImmunoTech highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, Phase 2 clinical signals, and a strengthening global regulatory and intellectual property position. "The initiation of Phase 3 planning marks a critical step forward in our mission to bring Ampligen to patients with pancreatic cancer," said Thomas K. Equels, Chief Executive Officer of AIM. "With a growing body of positive late-stage pancreatic ductal adenocarcinoma clinical data, more than 100 subjects treated, Orphan Drug Designations in the U.S. and EU, and a strong global IP portfolio, we believe Ampligen has the potential to be a game-changing therapy in one of the most lethal cancers and a significant driver of long-term stockholder value."
AIM ImmunoTech Announces Preliminary Rights Offering Results of Approximately $1.8M
AIM ImmunoTech announced the preliminary results of its previously announced rights offering which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8M. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions. Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per Unit, consisting of one share of the Company's Series G Convertible Preferred Stock, and 2,000 Class G Common Stock Purchase Warrants to purchase the Company's Common Stock. The Company anticipates the closing of the Rights Offering will occur on or about March 6, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.
AIM ImmunoTech Partners with Thermo Fisher to Design Phase 3 Pancreatic Cancer Trial
AIM ImmunoTech (AIM) announced an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design AIM's anticipated Phase 3 clinical trial in the use of the Company's drug Ampligen in the treatment of late-stage pancreatic cancer. AIM CEO Thomas Equels states: "The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca's durvalumab in the treatment of late-stage pancreatic cancer is producing promising results. Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM's development of Ampligen as a therapy for pancreatic cancer. AIM's scientific team will work closely with Thermo Fisher's experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor. Pancreatic cancer is a deadly unmet medical need - and AIM believes that Ampligen could be a gamechanger in the treatment of pancreatic cancer."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。